StockData
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31

CASTLE BIOSCIENCES INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$32.16+0.20 (+0.64%)

Close on Oct 19, 2026

Market cap
$977.78M
P/E (TTM)
–
Dividend yield
0.00%

Earnings

Next report expected Nov 2, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 30, 2026After market close$103.50M––
Q1 FY2026
Ended Mar 31, 2026
May 6, 2026After market close$83.70M$-0.49$-0.49
Q4 FY2025
Ended Dec 31, 2025
Jan 13, 2026During market hours–––
Q3 FY2025
Ended Sep 30, 2025
Nov 3, 2025After market close$83.00M$-0.02$-0.02
Q2 FY2025
Ended Jun 30, 2025
Aug 4, 2025After market close$86.20M$0.16$0.15
Q1 FY2025
Ended Mar 31, 2025
May 5, 2025After market close$88.00M––
Q4 FY2024
Ended Dec 31, 2024
Jan 13, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Nov 4, 2024After market close$85.80M$0.08–
Q2 FY2024
Ended Jun 30, 2024
Aug 5, 2024After market close$87.00M$0.31–
Q1 FY2024
Ended Mar 31, 2024
May 2, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Jan 8, 2024Before market open–––

Company guidance

Outlook given with results on Jul 30, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
total revenue2026$365.00M to $375.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Castle Biosciences filed with the SEC